1. Hemodynamical Evaluation of a New Surgically Implanted Pulsatile Right Ventricular Assist Device Driven by a Conventional Intra-Aortic Balloon Pump Console.
- Author
-
Knigge S, Dogan G, Deniz E, Ismail Y, Optenhöfel J, Schana L, Merzah AS, Hanke JS, Ismail I, Malchin O, Bastos M, Popov AF, Weymann A, Ruhparwar A, Schmack B, and Schmitto JD
- Subjects
- Animals, Swine, Ventricular Dysfunction, Right physiopathology, Ventricular Dysfunction, Right surgery, Ventricular Dysfunction, Right therapy, Heart-Assist Devices, Hemodynamics physiology, Intra-Aortic Balloon Pumping instrumentation, Intra-Aortic Balloon Pumping methods, Pulsatile Flow physiology, Heart Failure surgery, Heart Failure therapy, Heart Failure physiopathology
- Abstract
Severe right heart failure, often overlooked and challenging to manage, has prompted a growing interest in innovative approaches to provide functional support. This study uses experimentation in large porcine models to introduce a novel prototype of a pulsatile mechanical circulatory support device and document its effects when deployed as a right ventricular assist device (RVAD). The pulsatile ventricular assist platform (pVAP), featuring a membrane pump driven by an intra-aortic balloon pump console, actively generates pulsatile flow to propel right ventricular blood into the pulmonary artery. This novel prototype demonstrates promising potential in addressing the challenges of right heart failure management. After preliminary in vitro assessments, the pVAP was tested on seven porcine models in a healthy state and after the induction of right ventricular failure. During the procedure, a set of standard ( ie , standard-of-care) hemodynamic measurements was obtained. Additionally, invasive pressure-volume loop analysis was employed to examine left ventricular hemodynamics. Results indicated that activation of the pVAP during right ventricular failure significantly improved systemic hemodynamics and enhanced left ventricular function. This study sheds light on the potential of the pVAP in managing right heart failure., Competing Interests: O.M. is the CEO of PulseCath BV. M.B. receives personal fees from PulseCath BV. The other authors have no conflicts of interest to report., (Copyright © ASAIO 2024.)
- Published
- 2024
- Full Text
- View/download PDF